9-27-9

IFW

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON EP 2 2004 AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

ATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-1450

Elaine C. Stracker

OLD E 2004

PATENT

Attorney's Docket No.: 00043.04CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/735,199

Filed:

12/12/2003

Title

DELIVERY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS

THROUGH AN INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

Date:

SEP. 24 2004

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/735,199 Application Number TRANSMITTAL 12/12/2003 Filing Date **FORM** Joshua D. Rabinowitz First Named Inventor (to be used for all correspondence after initial filing) Art Unit Not yet known **Examiner Name** To be assigned Total Number of Pages in This Submission Attorney Docket Number 00043.04CON **ENCLOSURES** (check all that apply) After Allowance communication Drawing(s) Fee Transmittal Form to Group Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to Group Petition Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert a **Proprietary Information** After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Other Enclosure(s) (please **Extension of Time Request** Terminal Disclaimer identify below): Request for Refund Express Abandonment Request Information Disclosure Statement CD, Number of CD(s) ____ Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Info. Discl. Statemetn (2 pp.) Incomplete Application Form 1449 (3 copies, 8 pages each) Copy of creferences 169 Response to Missing Parts Return Postcard under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Signature

Signatur

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Typed or printed name Elaine C. Stracker

Signature Date SEP. 2 4 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet 1 of 8

Form	n P &Q- 144	19 25			
	VI AN	- MARKE			
Γ	NFORMA	TION I	DISCLO	SURE (CITAT

MATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00	043. 04 CON	Application Number: 10/735,199				
Applicant:	Joshua D. RABI	NOWITZ et al.				

Filing Date: 12/12/2003 Group Art Unit: Not Yet Known

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date I Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	05/27/1980	Re. 30,285	Babington			
	3.	01/23/1990	4,895,719	Radhakrishnun et al.			
	4.	09/17/1991	5,049,389	Radhakrishnun			
	5.	02/14/1995	5,388,574	Ingebrethsen			
	6.	08/13/1996	5,544,646	Lloyd et al.			
	7.	12/09/1997	5,694,919	Rubsamen et al.			
	8.	03/10/1998	5,724,957	Rubsamen et al.			
	9.	04/07/1998	5,735,263	Rubsamen et al.			
	10.	04/14/1998	5,738,865	Baichwal et al.			
	11.	06/02/1998	5,758,637	Ivri et al.			
	12.	06/29/1999	5,915,378	Lloyd et al.			
-	13.	08/10/1999	5,934,272	Lloyd et al.			
	14.	09/28/1999	5,957,124	Lloyd et al.			
	15.	10/05/1999	5,960,792	Lloyd et al.			
<u> </u>	16.	11/30/1999	5,993,805	Sutton et al.			
	17.	03/28/2000	6,041,777	Faithfull et al.			
	18.	04/18/2000	6,051,566	Bianco			
	19.	08/01/2000	6,095,134	Sievers et al.			
	20.	08/01/2000	6,095,153	Kessler et al.			
	21.	08/15/2000	6,102,036	Slutsky et al.			
	22.	06/05/2001	6,241,969	Saidi et al.			
	23.	07/03/2001	6,255,334	Sands			
	24.	10/09/2001	6,299,900	Reed et al.			
	25.	10/23/2001	6,306,431	Zhang et al.			
	26.	01/14/2003	6,506,762	Horvath et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Sheet 2 of 8

NFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessury) Filing Date: 12/12/2003 Group Art Unit: Not Yet Known				Docket Number: 00043. 04 CON Application Number: 10/735,199				
27.				Applicant:	Joshua D. R.A	ABINOWITZ et al.		
28. 07/15/2003 6,591,839 Meyer et al. 29. 09/06/2001 US 2001/0020147 Staniforth et al. 30. 03/28/2002 US 2002/0037828 Wilson et al. 31. 05/16/2002 US 2002/0058009 Bartus et al. 32. 05/23/2002 US 2002/006852 Cantor 34. 08/22/2002 US 2002/017823 Schuster et al. 35. 11/28/2002 US 2002/078841 Barker et al. 36. 01/02/2003 US 2003/0004142 Prior et al. 37. 02/13/2003 US 2003/0004142 Prior et al. 38. 08/04/2003 US 2003/0032638 Kim et al. RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 38. 08/04/2003 10/633,876 Hale et al. 39. 08/04/2003 10/633,877 Hale et al. 40. 12/30/2003 10/749,537 Rabinowitz et al. 41. 12/30/2003 10/749,537 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,279 Rabinowitz et al. 44. 01/27/2004 10/766,279 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,574 Rabinowitz et al. 47. 01/27/2004 10/766,634 Rabinowitz et al. 48. 01/27/2004 10/766,636 Rabinowitz et al. 49. 01/27/2004 10/766,634 Rabinowitz et al. 41. 01/27/2004 10/766,647 Rabinowitz et al. 42. 01/27/2004 10/766,567 Rabinowitz et al. 43. 01/27/2004 10/766,574 Rabinowitz et al. 44. 01/27/2004 10/766,634 Rabinowitz et al. 50. 01/29/2004 10/766,200 Rabinowitz et al. 51. 01/29/2004 10/768,200 Rabinowitz et al. 52. 01/29/2004 10/768,201 Rabinowitz et al. 53. 01/29/2004 10/768,201 Rabinowitz et al. 54. 01/29/2004 10/768,201 Rabinowitz et al. 55. 01/29/2004 10/768,201 Rabinowitz et al. 56. 01/29/2004 10/768,201 Rabinowitz et al. 57. 01/29/2004 10/768,201 Rabinowitz et al. 58. 01/29/2004 10/768,201 Rabinowitz et al.		(Use several sheets if necessary)			Filing Date:	12/12/2003	Group Art Unit:	Not Yet Known
28. 07/15/2003 6,591,839 Meyer et al. 29. 09/06/2001 US 2001/0020147 Staniforth et al. 30. 03/28/2002 US 2002/0037828 Wilson et al. 31. 05/16/2002 US 2002/0058009 Bartus et al. 32. 05/23/2002 US 2002/006852 Cantor 34. 08/22/2002 US 2002/017823 Schuster et al. 35. 11/28/2002 US 2002/078841 Barker et al. 36. 01/02/2003 US 2003/0004142 Prior et al. 37. 02/13/2003 US 2003/0004142 Prior et al. 38. 08/04/2003 US 2003/0032638 Kim et al. RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 38. 08/04/2003 10/633,876 Hale et al. 39. 08/04/2003 10/633,877 Hale et al. 40. 12/30/2003 10/749,537 Rabinowitz et al. 41. 12/30/2003 10/749,537 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,279 Rabinowitz et al. 44. 01/27/2004 10/766,279 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,574 Rabinowitz et al. 47. 01/27/2004 10/766,634 Rabinowitz et al. 48. 01/27/2004 10/766,636 Rabinowitz et al. 49. 01/27/2004 10/766,634 Rabinowitz et al. 41. 01/27/2004 10/766,647 Rabinowitz et al. 42. 01/27/2004 10/766,567 Rabinowitz et al. 43. 01/27/2004 10/766,574 Rabinowitz et al. 44. 01/27/2004 10/766,634 Rabinowitz et al. 50. 01/29/2004 10/766,200 Rabinowitz et al. 51. 01/29/2004 10/768,200 Rabinowitz et al. 52. 01/29/2004 10/768,201 Rabinowitz et al. 53. 01/29/2004 10/768,201 Rabinowitz et al. 54. 01/29/2004 10/768,201 Rabinowitz et al. 55. 01/29/2004 10/768,201 Rabinowitz et al. 56. 01/29/2004 10/768,201 Rabinowitz et al. 57. 01/29/2004 10/768,201 Rabinowitz et al. 58. 01/29/2004 10/768,201 Rabinowitz et al.							·	
28. 07/15/2003 6,591,839 Meyer et al. 29. 09/06/2001 US 2001/0020147 Staniforth et al. 30. 03/28/2002 US 2002/0037828 Wilson et al. 31. 05/16/2002 US 2002/0058009 Bartus et al. 32. 05/23/2002 US 2002/006852 Cantor 34. 08/22/2002 US 2002/017823 Schuster et al. 35. 11/28/2002 US 2002/078841 Barker et al. 36. 01/02/2003 US 2003/0004142 Prior et al. 37. 02/13/2003 US 2003/0004142 Prior et al. 38. 08/04/2003 US 2003/0032638 Kim et al. RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 38. 08/04/2003 10/633,876 Hale et al. 39. 08/04/2003 10/633,877 Hale et al. 40. 12/30/2003 10/749,537 Rabinowitz et al. 41. 12/30/2003 10/749,537 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,279 Rabinowitz et al. 44. 01/27/2004 10/766,279 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,574 Rabinowitz et al. 47. 01/27/2004 10/766,634 Rabinowitz et al. 48. 01/27/2004 10/766,636 Rabinowitz et al. 49. 01/27/2004 10/766,634 Rabinowitz et al. 41. 01/27/2004 10/766,647 Rabinowitz et al. 42. 01/27/2004 10/766,567 Rabinowitz et al. 43. 01/27/2004 10/766,574 Rabinowitz et al. 44. 01/27/2004 10/766,634 Rabinowitz et al. 50. 01/29/2004 10/766,200 Rabinowitz et al. 51. 01/29/2004 10/768,200 Rabinowitz et al. 52. 01/29/2004 10/768,201 Rabinowitz et al. 53. 01/29/2004 10/768,201 Rabinowitz et al. 54. 01/29/2004 10/768,201 Rabinowitz et al. 55. 01/29/2004 10/768,201 Rabinowitz et al. 56. 01/29/2004 10/768,201 Rabinowitz et al. 57. 01/29/2004 10/768,201 Rabinowitz et al. 58. 01/29/2004 10/768,201 Rabinowitz et al.	ļ	27	02/04/2003	6 514 482	Rartus et al		· · · · · · · · · · · · · · · · · · ·	
29. 09/06/2001 US 2001/0020147 Staniforth et al. 30. 03/28/2002 US 2002/0037828 Wilson et al. 31. 05/16/2002 US 2002/0058009 Bartus et al. 32. 05/23/2002 US 2002/0061281 Osbakken et al. 33. 07/04/2002 US 2002/0086852 Cantor 34. 08/22/2002 US 2002/0112723 Schuster et al. 35. 11/28/2002 US 2002/0176841 Barker et al. 36. 01/02/2003 US 2003/0004142 Prior et al. 37. 02/13/2003 US 2003/0032638 Kim et al. RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 38. 08/04/2003 10/633,877 Hale et al. 40. 12/30/2003 10/749,537 Rabinowitz et al. 41. 12/30/2003 10/749,539 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,279 Rabinowitz et al. 44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,634 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,634 Rabinowitz et al. 48. 01/28/2004 10/766,634 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,205 Rabinowitz et al. 51. 01/29/2004 10/768,207 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/768,293 Rabinowitz et al.	+		1					
30.	+	-	+	 	 	-		
31. 05/16/2002 US 2002/0058009 Bartus et al. 32. 05/23/2002 US 2002/0061281 Osbakken et al. 33. 07/04/2002 US 2002/0086852 Cantor 34. 08/22/2002 US 2002/0112723 Schuster et al. 35. 11/28/2002 US 2002/0176841 Barker et al. 36. 01/02/2003 US 2003/0004142 Prior et al. 37. 02/13/2003 US 2003/0032638 Kim et al. RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 38. 08/04/2003 10/633,876 Hale et al. 40. 12/30/2003 10/749,537 Rabinowitz et al. 41. 12/30/2003 10/749,539 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,566 Rabinowitz et al. 44. 01/27/2004 10/766,574 Rabinowitz et al. 45. 01/27/2004 10/766,634 Rabinowitz et al. 46. 01/27/2004 10/766,647 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/766,205 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,207 Rabinowitz et al. 51. 01/29/2004 10/768,208 Rabinowitz et al. 52. 01/29/2004 10/768,209 Rabinowitz et al. 53. 01/30/2004 10/768,209 Rabinowitz et al. 55. 01/29/2004 10/768,209 Rabinowitz et al. 57. 01/29/2004 10/768,209 Rabinowitz et al. 58. 01/29/2004 10/768,209 Rabinowitz et al. 59. 01/29/2004 10/768,209 Rabinowitz et al. 50. 01/29/2004 10/768,209 Rabinowitz et al.	1		 					
32. 05/23/2002 US 2002/0061281 Osbakken et al. 33. 07/04/2002 US 2002/0086852 Cantor 34. 08/22/2002 US 2002/0112723 Schuster et al. 35. 11/28/2002 US 2002/0176841 Barker et al. 36. 01/02/2003 US 2003/0004142 Prior et al. 37. 02/13/2003 US 2003/0032638 Kim et al. RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 38. 08/04/2003 10/633,876 Hale et al. 40. 12/30/2003 10/633,877 Hale et al. 40. 12/30/2003 10/749,537 Rabinowitz et al. 41. 12/30/2003 10/749,537 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,279 Rabinowitz et al. 44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/766,647 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,205 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/768,293 Rabinowitz et al. 54. 01/29/2004 10/768,293 Rabinowitz et al. 55. 01/29/2004 10/768,293 Rabinowitz et al. 56. 01/29/2004 10/768,293 Rabinowitz et al. 57. 01/29/2004 10/768,293 Rabinowitz et al. 58. 01/29/2004 10/768,293 Rabinowitz et al. 59. 01/29/2004 10/768,293 Rabinowitz et al. 50. 01/29/2004 10/768,293 Rabinowitz et al.	-							
33. 07/04/2002 US 2002/0086852 Cantor			 				·	
34. 08/22/2002 US 2002/0112723 Schuster et al. 35. 11/28/2002 US 2002/0176841 Barker et al. 36. 01/02/2003 US 2003/0004142 Prior et al. 37. 02/13/2003 US 2003/0032638 Kim et al. RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 38. 08/04/2003 10/633,876 Hale et al. 39. 08/04/2003 10/633,877 Hale et al. 40. 12/30/2003 10/749,537 Rabinowitz et al. 41. 12/30/2003 10/749,539 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,566 Rabinowitz et al. 44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,634 Rabinowitz et al. 48. 01/28/2004 10/766,647 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,205 Rabinowitz et al. 51. 01/29/2004 10/768,220 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/768,293 Rabinowitz et al.	ļ					•		
35. 11/28/2002 US 2002/0176841 Barker et al.	<u> </u>							····
36. 01/02/2003 US 2003/0004142 Prior et al.	ļ							
37.	<u> </u>	35.	 					
RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 38. 08/04/2003 10/633,876 Hale et al. 39. 08/04/2003 10/749,537 Rabinowitz et al. 40. 12/30/2003 10/749,539 Rabinowitz et al. 41. 12/30/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,279 Rabinowitz et al. 44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/766,647 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,205 Rabinowitz et al. 51. 01/29/2004 10/768,220 Rabinowitz et al. 52. 01/29/2004 10/768,281 Rabinowitz et al. 53. 01/30/2004 10/768,293 Rabinowitz et al.		36.	01/02/2003	US 2003/0004142				
RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 38. 08/04/2003 10/633,876 Hale et al. 39. 08/04/2003 10/633,877 Hale et al. 40. 12/30/2003 10/749,537 Rabinowitz et al. 41. 12/30/2003 10/749,539 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,279 Rabinowitz et al. 44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/766,647 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,205 Rabinowitz et al. 51. 01/29/2004 10/768,220 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/768,293 Rabinowitz et al.	<u></u>	37.	02/13/2003	US 2003/0032638	Kim et al.			
38. 08/04/2003 10/633,876 Hale et al. 39. 08/04/2003 10/633,877 Hale et al. 40. 12/30/2003 10/749,537 Rabinowitz et al. 41. 12/30/2003 10/749,539 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,579 Rabinowitz et al. 44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/767,115 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		RELA	TED ALEXZA	MOLECULAR DEL	IVERY CORPOI	RATION PA	TENT DOCUM	
40. 12/30/2003 10/749,537 Rabinowitz et al.				-T				
41. 12/30/2003 10/749,539 Rabinowitz et al. 42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,579 Rabinowitz et al. 44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/767,115 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,293 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		39.	08/04/2003	10/633,877	Hale et al.			
42. 01/27/2004 10/766,149 Rabinowitz et al. 43. 01/27/2004 10/766,279 Rabinowitz et al. 44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/767,115 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		40.	12/30/2003	10/749,537	Rabinowitz et al.			
43. 01/27/2004 10/766,279 Rabinowitz et al. 44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/767,115 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		41.	12/30/2003	10/749,539	Rabinowitz et al.			
44. 01/27/2004 10/766,566 Rabinowitz et al. 45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/767,115 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		42.	01/27/2004	10/766,149	Rabinowitz et al.			
45. 01/27/2004 10/766,574 Rabinowitz et al. 46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/767,115 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		43.	01/27/2004	10/766,279	Rabinowitz et al.			
46. 01/27/2004 10/766,634 Rabinowitz et al. 47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/767,115 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		44.	01/27/2004	10/766,566	Rabinowitz et al.			
47. 01/27/2004 10/766,647 Rabinowitz et al. 48. 01/28/2004 10/767,115 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		45.	01/27/2004	10/766,574	Rabinowitz et al.			
48. 01/28/2004 10/767,115 Rabinowitz et al. 49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		46.	01/27/2004	10/766,634	Rabinowitz et al.			
49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.		47.	01/27/2004	10/766,647	Rabinowitz et al.			
49. 01/29/2004 10/768,205 Rabinowitz et al. 50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.	-	48.	01/28/2004		Rabinowitz et al.			
50. 01/29/2004 10/768,220 Rabinowitz et al. 51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.								
51. 01/29/2004 10/768,281 Rabinowitz et al. 52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.					Rabinowitz et al.			
52. 01/29/2004 10/768,293 Rabinowitz et al. 53. 01/30/2004 10/769,046 Rabinowitz et al.					Rabinowitz et al.			
53. 01/30/2004 10/769,046 Rabinowitz et al.			·					
					 			-
,, , , , , , , , , , , , , , , , , , ,				<u> </u>	 			
55. 01/29/2004 10/769,157 Rabinowitz et al.				 	 			
EXAMINER DATE CONSIDERED:	-				<u> </u>			

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Sheet 3 of 8

Docket Number: 00043.04 CON Application Number: 10/735,199 Form PTO-1449 Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION Filing Date: 12/12/2003 Group Art Unit: Not Yet Known (Use several sheets if necessary) 10/769,197 Rabinowitz et al. 56. 01/29/2004 Rabinowitz et al. 02/09/2004 10/775,583 Rabinowitz et al. 58. 02/09/2004 10/775,586 59. 03/03/2004 10/791,915 Hale et al. 10/792,001 Rabinowitz et al. 60. 03/03/2004 03/03/2004 61. 10/792,012 Hale et al. 62. 03/03/2004 10/792,013 Rabinowitz et al. 63. 03/03/2004 10/792,096 Hale et al. 64. 03/03/2004 10/792,239 Hale et al. 65. 03/31/2004 10/813,721 Rabinowitz et al. Rabinowitz et al. 66. 03/31/2004 10/813,722 Rabinowitz et al. 67. 03/31/2004 10/814,690 68. 03/31/2004 10/814,998 Rabinowitz et al. 04/01/2004 10/815,527 Rabinowitz et al. 69. 70. 04/01/2004 10/816,407 Rabinowitz et al. Rabinowitz et al. 71. 04/01/2004 10/816,492 72. 04/01/2004 10/816,567 Rabinowitz et al. 73. 08/04/2004 Hale et al. 10/912,462 74. 01/23/2003 US 2003/0015196 Hodges et al. 75. 04/03/2003 US 2003/0062042 Wensley et al. 76. 11/13/2003 US 2003/0209240 Hale et al. Rabinowitz et al. 77. 01/02/2003 US 2003/0000518 78. 01/09/2003 Rabinowitz et al. US 2003/0005924 79. 01/09/2003 US 2003/0005925 Hale et al. 80. 01/09/2003 US 2003/0007933 Rabinowitz et al. 01/09/2003 US 2003/0007934 Rabinowitz et al. 81. 82. 01/16/2003 US 2003/0012737 Rabinowitz et al. 83. 01/16/2003 US 2003/0012738 Rabinowitz et al. US 2003/0012740 Rabinowitz et al. 84. 1/16/2003 85. 01/23/2003 US 2003/0015189 Rabinowitz et al.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Sheet 4 of 8 Application Number: 10/735,199 Docket Number: 00043.04 CON Form PTO-1449 Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION Filing Date: 12/12/2003 Group Art Unit: Not Yet Known (Use several sheets if necessary) 86. 01/23/2003 US 2003/0015190 Rabinowitz et al. US 2003/0017114 Rabinowitz et al. 87. 01/23/2003 US 2003/0017115 Rabinowitz et al. 88. | 01/23/2003 Rabinowitz et al. US 2003/0017116 89. 01/23/2003 US 2003/0017117 Rabinowitz et al. 01/23/2003 Rabinowitz et al. 01/23/2003 US 2003/0017118 91. US 2003/0017119 Rabinowitz et al. 92. 01/23/2003 Rabinowitz et al. US 2003/0017120 01/23/2003 93. 94. 1/30/2003 US 2003/0021753 Rabinowitz et al. US 2003/0021754 Rabinowitz et al. 01/30/2003 95. 01/30/2003 US 2003/0021755 Hale et al. 96: Hodges et al. 97. 02/20/2003 US 2003/0035776 Rabinowitz et al. 98. 05/15/2003 US 2003/0091511 Hale et al. US 2004/010148 99. 05/27/2004 Rabinowitz 100. 07/31/2003 US 2003/0138382 US 2003/0206869 Rabinowitz et al. 101. 11/06/2003 Rabinowitz et al. US 2004/0009128 01/15/2004 102. US 2004/0096402 Hodges et al. 103. 05/20/2004 US 2004/0099269 Hale et al. 104. 05/27/2004 06/03/2004 US 2004/0105818 Hale et al. 105. Hale et al. US 2004/0105819 106. 06/03/2004 Rahinowitz et al. 107. 07/01/2004 US 2004/0126326 Rabinowitz et al. US 2004/0126328 108. 07/01/2004 Rabinowitz et al. 109. 07/01/2004 US 2004/0126329 Rabinowitz et al. 110. 07/01/2004 US 2004/0127481 Rabinowitz et al. 111. 07/01/2004 US 2004/0127490 08/12/2004 US 2004/0156788 Rabinowitz et al. 112. 08/12/2004 US 2004/0156789 Rabinowitz et al. 113. 114. 8/12/2004 US 2004/0156790 Rabinowitz et al. 08/12/2004 US 2004/0156791 Rabinowitz et al. 115. DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Sheet 5 of 8

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) Docket Number: 00043. 04 CON Application Number: 10/735,199 Applicant: Joshua D. RABINOWITZ et al. Filing Date: 12/12/2003 Group Art Unit: Not Yet Known

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	116.	03/14/1990	EP 0 358 114	Europe			
	117.	07/20/1994	EP 0 606 486	Europe			
	118.	07/03/2001	EP 1 080 720	Europe			
	119.	06/13/1991	WO 91/07947	WIPO			
	120.	04/16/1992	WO 92/05781	WIPO .			
	121.	04/11/1996	WO 96/09846	WIPO			
	122.	05/09/1996	WO 96/13161	WIPO			:
	123.	05/09/1996	WO 96/13290	WIPO			
	124.	05/09/1996	WO 96/13291	WIPO		·	
	125.	05/09/1996	WO 96/13292	WIPO		·	
	126.	10/03/1996	WO 96/30068	WIPO			
	127.	08/07/1997	WO 97/27804	WIPO			
	128.	05/28/1998	WO 98/22170	WIPO			
	129.	07/23/1998	WO 98/31346	WIPO			
	130.	08/27/1998	WO 98/36651	WIPO			
	131.	04/08/1999	WO 99/16419	WIPO			
· · · · · · · · · · · · · · · · · · ·	132.	12/16/1999	WO 99/64094	WIPO			
	133.	01/06/2000	WO 00/00176	WIPO			
	134.	01/06/2000	WO 00/00215	WIPO			
	135.	05/18/2000	WO 00/27363	WIPO			
	136.	05/25/2000	WO 00/29053	WIPO			
	137.	9/17/2000	WO 00/47203	WIPO		·	
	138.	11/02/2000	WO 00/64940	WIPO			
· · · · · · · · · · · · · · · · · · ·	139.	11/09/2000	WO 00/66084	WIPO			
	140.	11/09/2000	WO 00/66206	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

								Sheet 6 of 8
10111110-1449				Docket Number	r: 10/735,199			
				Applicant: Joshua D. RABINOWITZ et al.				
		se several sheets if necessa		Filing Date:	12/12/2003		Group Art Unit:	Not Yet Known
		<u> </u>						
	141.	12/21/2000	WO 00/76673	WIPO				
	142.	01/25/2001	WO 01/05459	WIPO				
	143.	03/01/2001	WO 01/13957	WIPO		 		
	144.	03/28/2002	WO 02/24158	WIPO				
-				•				
			•					
,								
		•						
		•						
			•		,			
	•						•	
			•					
			·					
		•						
							,	
	٠				•			
,		•						
		•			•			
:								•
-				•			•	
EXAMINE	R:	,		DATE	CONSIDERE	D:		
				1				

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Sheet 7 of 8

Docket Number: 00043. 04 CON Application Number: 10/735,199 Form PTO-1449 Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION (Use several sheets if necessary) Filing Date: 12/12/2003 Group Art Unit: Not Yet Known

OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.) Examiner Ref. Title **Initials** No. 145. Bennett, R.L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief," Annual Surg. 195(6):700-705. Carroll, M.E. et al. (1990), "Cocaine-base smoking in rhesus monkeys: reinforcing and physiological 146. effects," Psychopharmacology (Berl). 102:443-450. 147. Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size," Z. Erkrank. 166:13-24. Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical 148. Simulations and Experiments for Bolus Tests," American Physiological Society. 966-974. 149. Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," Journal of Applied Physiology. 32(5):591-600. 150. Dershwitz, M., M.D., et al. (September 2000). "Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers," Anesthesiology, 93(3): 619-628. 151. Finlay, W.H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press; San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii. 152. Gonda, I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, The Lung: Scientific Foundations. Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294. 153. Hatsukami D, et al. (May 1990) "A method for delivery of precise doses of smoked cocaine-base to humans." Pharmacology Biochemistry & Behavior. 36(1):1-7. Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Range 154. 0.005-15 μm," J. Aerosol Sci. 17(5):811-822. Huizer, H., "Analytical studies on illicit heron. V. Efficacy of volatilization during heroin smoking." 155. Pharmaceutisch Weekblad Scientific Edition (1987), 9(4):203-211. 156. Hurt, R.D., MD and Robertson, C.R., PhD, (October 1998). "Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," JAMA 280(13):1173-1181. Lichtman, A.H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinociception 157. in Mice," Journal of Pharmacology and Experimental Therapeutics. 279(1):69-76. 158. Martin, B.R. and Lue, L.P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine," Journal of Analytical Toxicology 13:158-162.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Sheet 8 of 8

Form PTO-1449		Docket Number: 0	0043. 04 CON	Application Number	: 10/735,199		
	ION DISCLOSURE CITATION I AN APPLICATION	Applicant:	Joshua D. RAB	INOWITZ et al.			
(1)	Ise several sheets if necessary)	Filing Date:	12/12/2003	Group Art Unit:	Not Yet Known		
				•			
159.	Mattox, A.J. and Carroll, M.E., (1996) Psychopharmacology, 125:195-201.	. "Smoked hero	oin self-administr	ation in rhesus n	nonkeys,"		
160.	Meng, Y. et al. "Inhalation Studies Wi 173:201-224.	th Drugs of Ab	use, " NIDA Reso	earch Monograp	h, (1997)		
161.	161. Meng, Y., et al. (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure," <i>Drug and Alcohol Dependence</i> . 53:111-120.						
162.	162. Office Action mailed 8/13/2003 for US application 10/153,313 filed 05/21/2002 "DELIVERY BENZODIAZEPINES THROUGH AN INHALATION ROUTE"						
163.	Pankow, J.F. et al. (1997). "Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form Through the Action of Gaseous Ammonia," <i>Envron. Sci. Technol.</i> 31:2428-2433.						
164.	Pankow, J. (March 2000). ACS Conference-San Francisco-3/26/00. Chemistry of Tobacco Smoke. pp. 1-8.						
165.	Seeman, J. et al. (1999). "The Form of Nicotine in Tobacco. Thermal Transfer of Nicotine and Nicotine Acid Salts to Nicotine in the Gas Phase," J. Agric. Food Chem. 47(12):5133-5145.						
166.	166. Sekine, H. and Nakahara, Y. (1987). "Abuse of Smoking Methamphetamine Mixed with Tobacco: 1. Inhalation Efficiency and Pyrolysis Products of Methamphetamine," <i>Journal of Forensic Science</i> 32(5):1271-1280.						
167.	Vapotronics, Inc. (1998) located at http://www.vapotronics.com.au/banner.htm , 11 pages, (visited on June 5, 2000).						
168.	Ward, M.E. MD, et al. (December1997). "Morphine Pharmacokinetics after Pulmonary Administration from a Novel Aerosol Delivery System," Clinical Pharmacology & Therapeutics 62(6):596-609.						
169.	Wood, R.W. et al. (1996). "Generation Pyrolyzate, Methylecgonidine, and De Biochemistry & Behavior. 55(2):237-2	monstration of					

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.